"Lipoprotein(a)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.
| Descriptor ID |
D017270
|
| MeSH Number(s) |
D10.532.350 D12.776.521.400
|
| Concept/Terms |
Lipoprotein(a)- Lipoprotein(a)
- Lipoprotein Lp(a)
- Lipoprotein (a)
- Lipoprotein a
|
Below are MeSH descriptors whose meaning is more general than "Lipoprotein(a)".
Below are MeSH descriptors whose meaning is more specific than "Lipoprotein(a)".
This graph shows the total number of publications written about "Lipoprotein(a)" by people in this website by year, and whether "Lipoprotein(a)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 2001 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 7 | 0 | 7 |
| 2018 | 4 | 0 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 3 | 5 | 8 |
| 2023 | 1 | 4 | 5 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoprotein(a)" by people in Profiles.
-
Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk. BMC Med Genomics. 2024 10 24; 17(1):255.
-
Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
-
Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. J Am Coll Cardiol. 2024 Apr 23; 83(16):1511-1525.
-
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.
-
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024 Apr 23; 83(16):1529-1539.
-
Lipoprotein(a) in clinical practice: A guide for the clinician. Prog Cardiovasc Dis. 2023 Jul-Aug; 79:28-36.
-
High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner. Atherosclerosis. 2023 11; 384:117150.
-
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023 06; 374:107-120.